New Updates

• Overweight and Obesity and Progression to End-Stage Kidney Disease in Patients with Autosomal Dominant Polycystic Kidney Disease
• Open-label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease Receiving Tolvaptan Kiyotaka Uchiyama et.al. KI Report 2025
• Overview of ADPKD in Pregnancy Ruth E. Campbell et.al. KI Reports 2025
• Assessing Pain in Patients With Polycystic Kidney Disease: Opportunities, Challenges, and Insights Abdou Y. Omorou et.al. KI REPORTS 2024
• Kdigo ADPKD guidelines 2025

• Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Vijay Ivaturi et.al. Kidney360 5: 996–1001, 2024.

• Metformin reduces decline in the estimated glomerular filtration rate during progression of autosomal dominant polycystic kidney disease: a systematic review and meta-analysis F YAO et.al. European Review for Medical and Pharmacological Sciences , 2023; 27: 11904-11912.

• Prevalence of Renal Neoplasia in Autosomal Dominant Polycystic Kidney Disease: Systematic Review and Meta-Analysis. Anna M. Drake et.al. Nephron 2024;148:457–467.
• Biomarkers of Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Ahmad Ghanem et.al. Kidney International Reports (2024).
• Treatment of Autosomal-Dominant Polycystic Kidney Disease
• Gene Therapy Without a Vector: Harnessing the Wild-­ Type PKD1/2 Allele in ADPKD
• Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025

• Genetic Testing in Autosomal Dominant Polycystic Kidney Disease: Why It Matters in 2025 
  

Perspectives

• • Perspectives on Drug Development in Early ADPKD. DjalilaMekahli et.al. CJASN 17: 1555–1558, 2022.

  • All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: PRO. Meghana S. Eswarappa et.al. Kidney360 5: 492–494, 2024